Vasant Narasimhan's guest appearances

Vasant Narasimhan

Fortune 500 Daily 

Conversations with Mike Milken

TechCheck

Alex Gorsky

David Solomon

Freda Lewis-Hall

Ed Bastian

Doug McMillon

Tony Fadell

John Grisham

Marc Benioff

Charles Schwab

Paul Romer

Kurt Newman

Steve Ballmer

Mellody Hobson

Denise Johnson

Jennifer Morgan

OwlTail

Our anchors begin today’s show breaking down the recent revaluation across tech stocks with CNBC’s Dom Chu and NYU Stern School of Business Professor Aswath Damodaran. Then, Medtronic CEO Geoffrey Martha discusses biotech advancements in 2023, and our Julia Boorstin explores potential catalysts for the media sector. Next, we cover crypto exchange Coinbase cutting 20% of its workforce with CNBC’s Kate Rooney and MoffettNathanson Partner Lisa Ellis. Later, Novartis CEO Vasant Narasimhan offers his outlook for health care, and CNBC’s Seema Mody reports on large institutional investors betting big on China.

Medtronic CEO Geoffrey Martha on Biotech Developments, Coinbase Announces Layoffs & Novartis CEO Vasant Narasimhan Shares Health Care Outlook 1/10/23

You’re listening to the Fortune 500 Daily.  The companies you know, the insight you need. Support for this podcast and the following message comes from TD Ameritrade.

You’re listening to the Fortune 500 Daily. The companies you know, the insight you need. Support for this podcast and the following message comes from TD Ameritrade.

Vasant Narasimhan, CEO, Novartis

Vas Narasimhan, CEO, Novartis -  “Our thinking is, how do we create a protease inhibitor that could work on future coronaviruses, not just the current coronavirus? … Fundamentally, our ability to withstand pandemics is likely going to center around our ability to think of this more as a defense topic than a health topic.” As the CEO of one of the largest pharmaceutical companies in the world, Vas Narasimhan knows what a unique moment in history this is. That’s why he’s spending hundreds of millions of dollars in research and development to attack COVID-19 from a variety of angles. Among these are protease inhibitors, monoclonal antibodies, and “glue degraders” that help dissolve critical proteins in the virus. As one of the world’s largest producers of hydroxychloroquine, they are also watching ongoing testing of that antimalarial drug. If the tests show it to be safe and effective, Novartis is ready to donate 130 million doses to start, and more if needed. For a company that last year produced more than 72 billion doses of medicine for nearly 800 million patients, ramping up to a global scale is a challenge Narasimhan and his company are eager to accept.

Vas Narasimhan, CEO, Novartis - “Our thinking is, how do we create a protease inhibitor that could work on future coronaviruses, not just the current coronavirus? … Fundamentally, our ability to withstand pandemics is likely going to center around our ability to think of this more as a defense topic than a health topic.” As the CEO of one of the largest pharmaceutical companies in the world, Vas Narasimhan knows what a unique moment in history this is. That’s why he’s spending hundreds of millions of dollars in research and development to attack COVID-19 from a variety of angles. Among these are protease inhibitors, monoclonal antibodies, and “glue degraders” that help dissolve critical proteins in the virus. As one of the world’s largest producers of hydroxychloroquine, they are also watching ongoing testing of that antimalarial drug. If the tests show it to be safe and effective, Novartis is ready to donate 130 million doses to start, and more if needed. For a company that last year produced more than 72 billion doses of medicine for nearly 800 million patients, ramping up to a global scale is a challenge Narasimhan and his company are eager to accept.

Ep. 21: Ramping Up, With Novartis's Vasant Narasimhan